Isomorphic Labs Raises $5 Billion in Series C Funding
Isomorphic Labs has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, according to the company’s November 17, 2026 announcement. The company said the funding is for further work on its AI drug-design technology and the development of medicine candidates toward clinical trials.
Its spending plans cover improvements to the drug-design engine and research in additional areas of biology. Isomorphic also said it plans to build infrastructure for translational work and clinical development as it moves candidates toward trials.
According to Isomorphic, its proprietary engine, IsoDDE, combines AI simulation models to explore possible chemical structures and assist with molecule design and refinement. The company said the models cover different therapeutic areas and drug modalities.
For its own oncology and immunology programs, as well as projects involving partners, Isomorphic said preclinical results were positive. That description was not accompanied by detailed preclinical data, according to FierceBiotech’s report dated November 17, 2026.
Beyond the two co-leads, participants in the financing included Alphabet, Andreessen Horowitz and other new investors, according to Isomorphic. The company also confirmed participation by every existing investor it identified: Temasek, Thrive Capital, MGX, GV, CapitalG and the UK Sovereign AI Fund.
The Series C follows an earlier financing announcement this year. On May 12, 2026, Isomorphic announced a Series B round totaling $2.1 billion.
* This article is based on publicly available information at the time of writing.